Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

被引：0
|
作者：
Chen, Robert W. [1 ]
Gopal, Ajay K. [2 ]
Smith, Scott E. [3 ]
Ansell, Stephen M. [4 ]
Rosenblatt, Joseph D. [5 ]
Savage, Kerry J. [6 ]
Connors, Joseph M. [7 ]
Engert, Andreas [8 ]
Larsen, Emily K. [9 ]
Sievers, Eric L. [9 ]
Younes, Anas [10 ]
机构：
[1] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA 91010 USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Med Ctr, Seattle, WA 98195 USA
[3] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Mayo Clin, Div Hematol, Rochester, MN USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[6] BC Canc Agcy Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada
[7] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada
[8] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[9] Seattle Genet Inc, Bothell, WA USA
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3689.3689
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3689
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
    Angelopoulou, Maria K.
    Vassilakopoulos, Theodoros P.
    Batsis, Ioannis
    Sakellari, Ioanna
    Gkirkas, Konstantinos
    Pappa, Vasiliki
    Giannoulia, Panagiota
    Apostolidis, Ioannis
    Apostolopoulos, Christos
    Roussou, Paraskevi
    Panayiotidis, Panayiotis
    Dimou, Maria
    Kyrtsonis, Marie-Christine
    Palassopoulou, Maria
    Vassilopoulos, Georgios
    Moschogiannis, Maria
    Kalpadakis, Christina
    Margaritis, Dimitrios
    Spyridonidis, Alexander
    Michalis, Eurydiki
    Anargyrou, Konstantinos
    Repousis, Panagiotis
    Hatzimichael, Eleutheria
    Bousiou, Zoi
    Poulakidas, Elias
    Grentzelias, Dimitrios
    Harhalakis, Nikolaos
    Pangalis, Gerassimos A.
    Anagnostopoulos, Achilles
    Tsirigotis, Panagiotis
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 174 - 181
  • [32] Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2018, 131 (11) : 1183 - 1194
  • [33] Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience
    Ozbalak, Murat
    Salihoglu, Ayse
    Soysal, Teoman
    Karadogan, Ihsan
    Paydas, Semra
    Ozdemir, Evren
    Yildiz, Birol
    Karadurmus, Nuri
    Kaynar, Leylagul
    Yagci, Munci
    Ozkocaman, Vildan
    Topcuoglu, Pervin
    Ozcan, Muhit
    Birtas, Elif
    Goker, Hakan
    Ferhanoglu, Burhan
    ANNALS OF HEMATOLOGY, 2020, 99 (02) : 301 - 307
  • [34] A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
    Zhi-Gang Cao
    Hong-Wei Zhou
    Chao-Jin Peng
    Mo Liu
    Yu Du
    Qing-Ming Yang
    ChineseJournalofCancer, 2013, 32 (09) : 520 - 523
  • [35] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: SINGLE CENTER EXPERIENCE
    Valiev, Timur
    Tsaplina, Nataly
    Kirgizov, Kirill
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S589 - S589
  • [36] Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience
    Murat Özbalak
    Ayşe Salihoğlu
    Teoman Soysal
    İhsan Karadoğan
    Semra Paydaş
    Evren Özdemir
    Birol Yıldız
    Nuri Karadurmuş
    Leylagül Kaynar
    Münci Yagci
    Vildan Özkocaman
    Pervin Topçuoğlu
    Muhit Özcan
    Elif Birtaş
    Hakan Göker
    Burhan Ferhanoglu
    Annals of Hematology, 2020, 99 : 301 - 307
  • [37] Importance of consolidation in patients with relapsed/refractory Hodgkin's lymphoma responders to Brentuximab Vedotin
    Machet, Antoine
    Cayssials, Emilie
    Leleu, Xavier
    Guidez, Stephanie
    HEMATOLOGIE, 2016, 22 (04): : 248 - +
  • [38] Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma
    Pro, Barbara
    Advani, Ranjana H.
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Huebner, Dirk
    Kennedy, Dana A.
    Shustov, Andrei R.
    BLOOD, 2013, 122 (21)
  • [39] Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience
    Ferhanoglu, A. Burhan
    Ozbalak, Murat
    Salihoglu, Ayse
    Soysal, Teoman
    Karadogan, Ihsan
    Paydas, Semra
    Ozdemir, Evren
    Yildiz, Birol
    Karadurmus, Nuri
    Kaynar, Leylagul
    Yegin, Zeynep Arzu
    Ozbalak, Ezgi Pinar
    Sucak, Gulsan
    Ozkocaman, Vildan
    Topcuoglu, Pervin
    Ozcan, Muhit
    Birtas, Elif
    Goker, Hakan
    BLOOD, 2017, 130
  • [40] Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Rosenzweig, Jaclyn
    Mauguen, Audrey
    Buhtoiarov, Ilia
    Cuglievan, Branko
    Dave, Hema
    Deyell, Rebecca J.
    Flerlage, Jamie E.
    Franklin, Anna K.
    Krajewski, Jennifer
    Leger, Kasey J.
    Marks, Lianna J.
    Norris, Robin E.
    Pacheco, Martha
    Willen, Faye
    Yan, Adam Paul
    Harker-Murray, Paul D.
    Giulino-Roth, Lisa
    BLOOD ADVANCES, 2023, 7 (13) : 3225 - 3231
12345